Wakil'S Institute Of Medical Science Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-06-2024
- Paid Up Capital ₹ 4.50 M
as on 15-06-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.17 M
as on 15-06-2024
- Revenue -11.42%
(FY 2023)
- Profit -90.38%
(FY 2023)
- Ebitda -4.41%
(FY 2023)
- Net Worth 1.96%
(FY 2023)
- Total Assets 26.14%
(FY 2023)
About Wakil'S Institute Of Medical Science
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.50 M.
The company currently has active open charges totaling ₹4.17 M.
Md Warsi, Farha Ahmed, Sajid Ahmed, and One other member serve as directors at the Company.
- CIN/LLPIN
U85320WB2018PTC229071
- Company No.
229071
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Wakil'S Institute Of Medical Science?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Md Warsi  | Director | 25-Mar-2022 | Current |
| Farha Ahmed | Director | 30-Nov-2018 | Current |
| Sajid Ahmed | Director | 30-Nov-2018 | Current |
| Shahid Ahmed | Director | 30-Nov-2018 | Current |
Financial Performance and Corporate Structure Insights of Wakil'S Institute Of Medical Science.
Wakil'S Institute Of Medical Science Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 11.42% decrease. The company also saw a substantial fall in profitability, with a 90.38% decrease in profit. The company's net worth moved up by a moderate rise of 1.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wakil'S Institute Of Medical Science?
In 2023, Wakil'S Institute Of Medical Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Wakils Pharmaceuticals Private Limited
Active 2 years 6 monthsFarha Ahmed and Sajid Ahmed are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Mar 2023 | ₹2.89 M | Open |
Others Creation Date: 29 Dec 2021 | ₹1.28 M | Open |
How Many Employees Work at Wakil'S Institute Of Medical Science?
Unlock and access historical data on people associated with Wakil'S Institute Of Medical Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wakil'S Institute Of Medical Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wakil'S Institute Of Medical Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
